Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.43 |
| ▸ | LCAT | P04180 | 1/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352123 | 1.00 | ADRB1 (0.57) | ADRB1DPP4DPP7SYKHRH4 | |
| SCHEMBL5086363 | 1.00 | ADRB1 (0.57) | ADRB1DPP4DPP7SYKHRH4 | |
| SCHEMBL1350579 | 0.91 | ADRB1 (0.64) | ADRB1DPP4DPP7SYKFFAR4 | |
| Hydrochloric Acid SCHEMBL2000843 | 0.90 | ADRB1 (0.62) | ADRB1DPP4DPP7SYKFFAR4 | |
| SCHEMBL4471479 | 0.88 | ADRB1 (0.59) | ADRB1DPP4DPP7SYKHRH4 | |
| SCHEMBL16282946 | 0.86 | HRH4 (0.52) | ADRB1DPP4DPP7SYKHRH4 | |
| SCHEMBL22657621 | 0.83 | ADRB1 (0.57) | ADRB1DPP4DPP7FFAR4ACACB | |
| SCHEMBL31319979 | 0.81 | HRH4 (0.51) | DPP4SYKHRH4HRH3KARS1 | |
| SCHEMBL22186753 | 0.80 | HRH4 (0.45) | DPP4DPP7SYKHRH4HRH3 | |
| Hydrochloric Acid SCHEMBL28603225 | 0.79 | HRH4 (0.44) | DPP4DPP7SYKHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063078-B2 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | GLAXOSMITHKLINE LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2298757-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | SMITHKLINE BEECHAM PLC. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7528151-B2 | Heterocyclic urea derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| EP-1425277-B8 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2036902-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1603899-A1 | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078749-A1 | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
| EP-1425277-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SmithKline Beecham P.L.C. (GB) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022809-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | U2SURP, UMPS, SFPQ | ADRB1 675/4885DPP4 3198/4885DPP7 3596/4885 |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | TRPV1, OPRL1, UTS2R | ADRB1 124/4885DPP4 3195/4885DPP7 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.